Company (location)






Celgene Corp. (Summit, N.J.)



High-risk early breast cancer patients

Phase III Geparsepto data found a significantly higher DFS rate in patients receiving it compared to those receiving paclitaxel as part of a neoadjuvant treatment regimen (p=0.0044); rates of DFS were 87.1% vs. 80.7% at three years and 83.5% vs. 76.2% at four years, respectively


Daiichi Sankyo Co. Ltd. (Tokyo)


HER2-targeting antibody-drug conjugate

Breast cancer

Phase I data of 57 efficacy evaluable patients with HER2-positive metastatic breast cancer pre-treated with Kadcyla showed it produced an overall response rate (ORR) of 61.4% and a disease control rate (DCR) of 94.7%; in the 50 patients who were also pre-treated with Perjeta it produced an ORR of 62% and a DCR of 94%; of the 39 efficacy evaluable patients with hormone-receptor positive disease, it produced an ORR of 56.4% and a DCR of 92.3%; in 19 efficacy evaluable patients with heavily pretreated HER2 low-expressing breast cancer, the ORR was 31.6% and the DCR was 84.2%; in the subgroup of those HER2 low-expressing patients who also had hormone-receptor positive disease, the ORR was 31.3% with a DCR of 87.5%


Puma Biotechnology Inc. (Los Angeles)



Diarrhea caused by Nerlynx associated with trastuzumab-based adjuvant therapy

Interim results from the phase II CONTROL trial showed of the 137 patients who received the loperamide prophylaxis, 30.7% had grade 3 diarrhea; for the 64 patients taking loperamide plus budesonide, the incidence of grade 3 diarrhea was 26.6%; of the 120 patients who received loperamide plus colestipol, 10.8% had grade 3 diarrhea


Seattle Genetics Inc. (Bothell, Wash.)

Ladiratuz-umab vedotin

Antibody-drug conjugate targeting LIV-1

Metastatic triple-negative breast cancer

Phase I showed an objective response rate of 25%; the clinical benefit rate, which also included patients with stable disease lasting at least 24 weeks, was 28%: the median progression-free survival and median duration of response for 19 patients treated at the recommended dose of 2.5 mg/kg, with a maximum dose of 200 mg per cycle, was 12.1 weeks and 17.4 weeks, respectively



The date indicated refers to the BioWorld issue in which the news item can be found.

For more information about individual companies and/or products, see Cortellis.